type 2 diabetes
Endocrinology · 2005–2026
108decisions
42medicines
21carried consumer input
255individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tirzepatide Treatment of adults with inadequately controlled type 2 diabetes mellitus who are contraindicated, intolerant or inadequately controlled with SGLT2 inhibitors. | Mar 2026 | Deferred | 115 individuals National Aboriginal Community Controlled Health Organisation · Diabetes Alliance · Australian Institute |
| tirzepatide Treatment of adults with inadequately controlled type 2 diabetes mellitus who are contraindicated, intolerant or inadequately controlled with SGLT2 inhibitors. | Jul 2025 | Deferred | 115 individuals National Aboriginal Community Controlled Health Organisation · Diabetes Alliance · Australian Institute |
| pioglitazone Treatment of type 2 diabetes mellitus (T2DM). | May 2025 | Recommended with restriction | none received |
| dapagliflozin with sitagliptin Treatment of patients with Type 2 diabetes mellitus with an inadequate response to treatment with dual therapy of metformin and an inhibitor of sodium glucose… | Mar 2024 | Recommended with restriction | input received National Aboriginal Community Controlled Health Organisation |
| semaglutide Type 2 diabetes mellitus. The submission requested listing of a new strength (2 mg in 3 mL pre-filled pen) as a cost-minimised alternative to the existing 2 mg… | Nov 2024 | Recommended | 5 individuals |
| tirzepatide Treatment of adult patients with inadequately controlled type 2 diabetes mellitus who have comorbid severe obesity (BMI ≥35 kg/m²) or identify as Aboriginal… | Nov 2024 | Not recommended | 14 individuals National Aboriginal Community Controlled Health Organisation · Diabetes Australia |
| tirzepatide Treatment of adult patients with inadequately controlled type 2 diabetes as dual therapy in combination with metformin. | Jul 2023 | Not recommended | 2 individuals Diabetes Australia · National Aboriginal Community Controlled Health Organisation |
| semaglutide Type 2 diabetes management, available on the PBS for use in combination with metformin and/or sulfonylurea or with insulin. Temporary section 19A listing to… | Aug 2022 | Recommended with restriction | no section in document |
| dulaglutide Treatment of adults with type 2 diabetes mellitus who require treatment intensification to achieve glycaemic targets, as dual therapy in combination with… | May 2022 | Recommended with restriction | 1 individuals Diabetes Australia |
| dulaglutide Type 2 diabetes mellitus, as a temporary supply option during a shortage of the locally-sourced product. | Oct 2022 | Recommended with restriction | no section in document |
| semaglutide Treatment of Type 2 Diabetes Mellitus in combination with insulin and metformin (unless contraindicated or not tolerated) in patients with inadequate glycaemic… | Mar 2021 | Recommended with restriction | input received |
| dulaglutide Type 2 diabetes mellitus in combination with insulin and metformin (unless contraindicated or not tolerated), in patients with inadequate glycaemic control… | Jul 2020 | Noted | none received |
| semaglutide Treatment of adults with Type 2 Diabetes Mellitus with inadequate glycaemic control as dual therapy in combination with metformin or a sulfonylurea where… | Mar 2020 | Recommended with restriction | none received |
| exenatide Type 2 diabetes mellitus in patients with inadequate glycaemic control on metformin and/or a sulfonylurea. | Mar 2019 | Recommended with restriction | none received |
| insulin glargine with lixisenatide Treatment of adults with type 2 diabetes mellitus who have inadequate glycaemic control with basal insulin, to be used in combination with metformin or as… | Mar 2019 | Not recommended | 1 individuals |
| dulaglutide Type 2 diabetes mellitus in combination with insulin and metformin (unless contraindicated or not tolerated) in patients with inadequate glycaemic control… | Nov 2019 | Deferred | input received |
| semaglutide Treatment of patients with type 2 diabetes who have inadequate glycaemic control, as dual therapy in combination with metformin or a sulfonylurea where either… | Nov 2019 | Recommended with restriction | input received Australian Diabetes Society |
| ertugliflozin Type 2 diabetes mellitus in patients inadequately controlled with metformin or a sulfonylurea, for use as dual oral therapy. | Jul 2018 | Recommended | none received |
| ertugliflozin with sitagliptin Type 2 diabetes mellitus in patients with inadequate glycaemic control on metformin and a dipeptidyl peptidase 4 (DPP4) or sodium-glucose co-transporter 2… | Jul 2018 | Recommended with restriction | none received |
| ertugliflozin Treatment of type 2 diabetes in patients inadequately controlled with metformin or a sulfonylurea, for use in dual oral therapy with metformin or a… | Mar 2018 | Recommended with restriction | none received |
| insulin degludec with insulin aspart Treatment of adult patients with diabetes mellitus (type 1 and type 2) where insulin treatment is necessary, for improvement of glycaemic control in patients… | Mar 2018 | Recommended with restriction | none received |
| insulin glargine with lixisenatide Treatment of adults with Type 2 diabetes mellitus who have inadequate glycaemic control with basal insulin (in combination with metformin). | Mar 2018 | Not recommended | input received Diabetes Australia |
| insulin glargine with lixisenatide Type 2 diabetes mellitus in patients with inadequate glycaemic control on basal insulin, in combination with metformin. | Mar 2018 | Not recommended | input received Diabetes Australia |
| liraglutide To reduce the risk of cardiovascular events in patients with type 2 diabetes at high cardiovascular risk, as an adjunct to standard of care therapy. | Mar 2018 | Not recommended | none received |
| dapagliflozin with metformin Type 2 diabetes mellitus in combination with a dipeptidyl peptidase 4 (DPP4) inhibitor for patients with inadequate glycaemic control on dual oral therapy. | Jul 2017 | Deferred | none received |
| dapagliflozin Type 2 diabetes in combination with metformin and a dipeptidyl peptidase-4 (DPP4) inhibitor in patients with inadequate glycaemic control on dual therapy with… | Jul 2017 | Deferred | none received |
| dapagliflozin/saxagliptin Type 2 diabetes mellitus in adults with inadequate glycaemic control on dual therapy with metformin and a DPP4 inhibitor. | Jul 2017 | Not recommended | none received |
| liraglutide Treatment of patients with Type 2 diabetes mellitus and high cardiovascular risk in combination with metformin, sulfonylurea, or insulin. | Jul 2017 | Not recommended | input received Diabetes Australia · Australian Diabetes Society |
| empagliflozin with linagliptin Type 2 diabetes mellitus as triple oral therapy in combination with metformin in patients intolerant or contraindicated to a combination of metformin and a… | Mar 2017 | Not recommended | none received |
| dapagliflozin Type 2 Diabetes Mellitus as part of triple oral therapy with a DPP4 inhibitor (gliptin) and metformin in patients who have previously been stabilised on dual… | Nov 2017 | Recommended with restriction | none received |
| dulaglutide Type 2 diabetes mellitus in dual therapy with metformin, or triple therapy with metformin and sulfonylurea, in patients not achieving adequate glycaemic… | Nov 2017 | Recommended with restriction | input received |
| empagliflozin, linagliptin Type 2 Diabetes Mellitus in patients uncontrolled on dual oral therapy, for use in triple oral therapy (empagliflozin + linagliptin + metformin) in patients… | Nov 2017 | Recommended with restriction | none received |
| empagliflozin with linagliptin Type 2 diabetes mellitus in patients uncontrolled on dual oral therapy with a DPP4 inhibitor or SGLT2 inhibitor plus metformin (triple therapy); and in… | Nov 2017 | Recommended with restriction | none received |
| vildagliptin Treatment of type 2 diabetes mellitus in combination with insulin in patients not adequately controlled on insulin therapy with or without metformin. | Nov 2017 | Recommended with restriction | none received |
| exenatide Type 2 diabetes mellitus in combination with metformin and/or a sulfonylurea in patients who have not achieved adequate glycaemic control. | Mar 2016 | Recommended with restriction | no section in document |
| linagliptin Treatment of type 2 diabetes as triple oral therapy in combination with metformin and a sulfonylurea when dual therapy with metformin and a sulfonylurea does… | Mar 2016 | Recommended | none received |
| linagliptin Type 2 diabetes mellitus in combination with insulin, with or without metformin, when therapy with insulin (± metformin) does not provide adequate glycaemic… | Mar 2016 | Recommended with restriction | none received |
| vildagliptin Type 2 diabetes as part of triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate… | Mar 2016 | Recommended with restriction | none received |
| dapagliflozin and metformin extended release Type 2 diabetes mellitus in combination with insulin (add-on to insulin setting) or in triple oral therapy with metformin and sulfonylurea, in patients… | Jul 2015 | Recommended | no section in document |
| exenatide Type 2 diabetes mellitus as dual or triple therapy in combination with metformin and/or a sulfonylurea. | Jul 2015 | Recommended with restriction | 1 individuals |
| saxagliptin and metformin XR Treatment of type 2 diabetes mellitus in combination with a sulfonylurea (triple oral therapy) in patients with HbA1c greater than 7% despite treatment with… | Jul 2015 | Recommended with restriction | none received |
| saxagliptin Treatment of type 2 diabetes mellitus in combination with metformin and a sulfonylurea in patients with inadequate glycaemic control despite maximally… | Jul 2015 | Recommended with restriction | input received |
| sitagliptin Type 2 diabetes mellitus as part of triple oral therapy with metformin and a sulfonylurea, when therapy with both agents does not provide adequate glycaemic… | Jul 2015 | Recommended with restriction | none received |
| sitagliptin Type 2 diabetes mellitus in combination with insulin, with or without metformin, when therapy with insulin (±metformin) does not provide adequate glycaemic… | Jul 2015 | Recommended with restriction | none received |
| dapagliflozin Treatment of type 2 diabetes mellitus in combination with metformin and a sulfonylurea (triple oral therapy) in patients with inadequate glycaemic control… | Mar 2015 | Recommended | input received |
| exenatide Type 2 diabetes mellitus in combination with insulin (and metformin unless contraindicated or not tolerated), as an alternative to insulin intensification in… | Mar 2015 | Recommended with restriction | 1 individuals |
| empagliflozin Type 2 diabetes in combination with insulin, with or without metformin, when therapy with insulin (± metformin) does not provide adequate glycaemic control. | Nov 2015 | Recommended with restriction | none received |
| empagliflozin/metformin Type 2 diabetes mellitus where metformin alone does not provide adequate glycaemic control. Treatment offered as a fixed-dose combination (FDC) in dual… | Nov 2015 | Recommended with restriction | none received |
| empagliflozin Type 2 diabetes mellitus in combination with metformin and a sulfonylurea (triple oral therapy) when combination therapy with both agents does not provide… | Nov 2015 | Recommended with restriction | none received |
| sitagliptin Type 2 diabetes mellitus in combination with insulin, with or without metformin, in patients with inadequate glycaemic control despite treatment with insulin… | Nov 2015 | Not recommended | none received |
| dapagliflozin and metformin extended release Treatment of type 2 diabetes in patients with inadequate glycaemic control on metformin and a sulfonylurea, as a third-line agent. | Jul 2014 | Recommended with restriction | none received |
| dapagliflozin Type 2 diabetes mellitus in patients whose diabetes cannot be adequately controlled with metformin and a sulfonylurea, as an add-on therapy in combination with… | Jul 2014 | Not recommended | no section in document |
| empagliflozin Type 2 diabetes in combination with metformin or a sulfonylurea in patients unable to be adequately controlled by treatment with metformin and a sulfonylurea. | Jul 2014 | Recommended with restriction | none received |
| glucose indicator blood strips Blood glucose monitoring for patients receiving treatment under a GP Management Plan or Team Care Arrangements. | Jul 2014 | Recommended | no section in document |
| lixisenatide Type 2 diabetes mellitus in dual therapy with metformin, or triple therapy with metformin and a sulphonylurea. | Jul 2014 | Noted | input received |
| lixisenatide Type 2 diabetes mellitus in combination with basal insulin in patients inadequately controlled despite treatment with insulin and oral antidiabetic agents. | Jul 2014 | Recommended with restriction | none received |
| thiazolidinediones, glucagon-like peptide-1, sodium-glucose co-transporter 2 inhibitors Type 2 diabetes mellitus; proposed changes to PBS restrictions for third-line treatment options. | Jul 2014 | Deferred | no section in document |
| dapagliflozin Type 2 diabetes in combination with insulin, after failure of maximum tolerated doses of oral diabetes medicines, in place of insulin up-titration or… | Nov 2014 | Recommended with restriction | input received |
| glucose indicator blood strip Blood glucose monitoring in patients receiving treatment under a GP Management Plan or Team Care Arrangements. | Nov 2014 | Recommended with restriction | no section in document |
| alogliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% prior to initiation of a dipeptidyl… | Jul 2013 | Recommended with restriction | no section in document |
| canagliflozin Type 2 diabetes mellitus as dual oral combination therapy with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with… | Jul 2013 | Recommended with restriction | no section in document |
| dapagliflozin Type 2 diabetes mellitus as dual oral combination therapy with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with… | Jul 2013 | Recommended with restriction | no section in document |
| vildagliptin with metformin Type 2 diabetes as triple oral combination therapy (vildagliptin/metformin fixed-dose combination with a sulfonylurea) in patients whose HbA1c is greater than… | Jul 2013 | Recommended | no section in document |
| vildagliptin Type 2 diabetes mellitus in triple oral combination therapy with metformin and a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with… | Jul 2013 | Not recommended | no section in document |
| saxagliptin with metformin Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin alone, where a combination of metformin and a sulfonylurea… | Apr 2013 | Deferred | no section in document |
| linagliptin with metformin hydrochloride Type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin alone, where combination with sulfonylurea is contraindicated… | Mar 2013 | Deferred | no section in document |
| linagliptin with metformin hydrochloride Type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin alone, where a combination of metformin and a sulfonylurea is… | Mar 2013 | Deferred | no section in document |
| liraglutide Type 2 diabetes as dual combination therapy with metformin or a sulfonylurea in patients for whom a combination of metformin and a sulfonylurea is… | Mar 2013 | Recommended with restriction | unclear |
| saxagliptin with metformin Type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin alone, where combination metformin and sulfonylurea is… | Mar 2013 | Deferred | no section in document |
| alogliptin with metformin Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin, when a dipeptidyl peptidase 4 inhibitor is being… | Nov 2013 | Recommended with restriction | no section in document |
| exenatide Type 2 diabetes mellitus in dual combination therapy with metformin or a sulfonylurea, or in triple combination therapy with metformin and a sulfonylurea, in… | Nov 2013 | Recommended with restriction | no section in document |
| metformin and saxagliptin Type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin, where a combination of metformin and a sulfonylurea is… | Nov 2013 | Recommended with restriction | no section in document |
| metformin/sitagliptin Type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin, where a combination of metformin and a sulfonylurea is… | Nov 2013 | Recommended | no section in document |
| linagliptin Type 2 diabetes in combination with metformin and a sulfonylurea (triple therapy) in patients whose HbA1c is greater than 7% despite treatment with maximally… | Jul 2012 | Not recommended | no section in document |
| saxagliptin Treatment of type 2 diabetes in combination with insulin in patients whose HbA1c is greater than 7% despite treatment with insulin and oral anti-diabetic… | Jul 2012 | Not recommended | no section in document |
| linagliptin Type 2 diabetes in combination with metformin and a sulfonylurea (triple therapy) in patients with HbA1c greater than 7% despite treatment with maximally… | Jul 2012 | Not recommended | no section in document |
| saxagliptin Treatment of type 2 diabetes in combination with insulin in patients whose HbA1c is greater than 7% despite treatment with insulin and oral anti-diabetic… | Jul 2012 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, in patients whose HbA1c is greater than 7% despite prior treatment with either agent… | Mar 2012 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes in combination with insulin, in patients whose HbA1c is greater than 7% despite treatment with insulin and oral anti-diabetic agents, or… | Mar 2012 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes in combination with metformin or a sulfonylurea in patients with HbA1c greater than 7% despite prior treatment. | Mar 2012 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes in combination with insulin, in patients whose HbA1c is greater than 7% despite treatment with insulin and oral anti-diabetic agents, or… | Mar 2012 | Not recommended | no section in document |
| sitagliptin with simvastatin Type 2 diabetes mellitus and hypercholesterolaemia in patients currently receiving simvastatin who satisfy criteria for DPP-4 inhibitor use. | Nov 2012 | Recommended with restriction | no section in document |
| sitagliptin with simvastatin Type 2 diabetes mellitus and hypercholesterolaemia in patients currently receiving treatment with simvastatin and who satisfy the criteria for prescribing… | Nov 2012 | Recommended with restriction | no section in document |
| exenatide Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, and in triple combination therapy with metformin and a sulfonylurea, in patients who… | Jul 2011 | Recommended with restriction | no section in document |
| linagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either metformin or… | Jul 2011 | Recommended | no section in document |
| linagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, in patients with HbA1c greater than 7% despite treatment with either metformin or a… | Nov 2011 | Recommended with restriction | no section in document |
| linagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, in patients whose HbA1c is greater than 7% despite treatment with either metformin or… | Nov 2011 | Recommended with restriction | no section in document |
| liraglutide Type 2 diabetes as dual combination therapy with metformin or a sulphonylurea in patients for whom a combination of metformin and a sulphonylurea is… | Nov 2011 | Not recommended | unclear |
| saxagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either metformin or… | Mar 2010 | Recommended with restriction | no section in document |
| vildagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either agent alone,… | Mar 2010 | Recommended with restriction | no section in document |
| vildagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either agent alone,… | Mar 2010 | Recommended with restriction | no section in document |
| liraglutide Type 2 diabetes mellitus as combination therapy with metformin and/or a sulfonylurea in patients with insufficient glycaemic control despite maximally… | Nov 2010 | Recommended with restriction | no section in document |
| exenatide Adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea or a combination of… | Mar 2008 | Recommended | no section in document |
| sitagliptin Type 2 diabetes mellitus in combination with metformin or sulfonylurea when a combination of metformin and sulfonylurea is contraindicated or not tolerated, or… | Mar 2008 | Recommended with restriction | no section in document |
| exenatide Adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of… | Nov 2008 | Recommended with restriction | no section in document |
| exenatide Adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of… | Jul 2007 | Not recommended | no section in document |
| exenatide Adjunctive therapy in patients with type 2 diabetes no longer achieving glycaemic control despite optimal therapy with metformin and/or a sulfonylurea. | Jul 2007 | Not recommended | no section in document |
| insulin detemir Extension of listing to include people with type 2 diabetes who are not responsive to oral hypoglycaemic drugs. | Nov 2007 | Recommended with restriction | no section in document |
| pioglitazone hydrochloride Type 2 diabetes mellitus in triple oral therapy combination with metformin and a sulfonylurea when HbA1c remains greater than 7% despite maximally tolerated… | Nov 2007 | Recommended with restriction | no section in document |
| rosiglitazone maleate Type 2 diabetes mellitus, alone or in combination with other diabetes therapies, in patients whose HbA1c is greater than 7% prior to initiation of a… | Nov 2007 | Not recommended | no section in document |
| insulin detemir Extension of listing to include people with type 2 diabetes who are not responsive to oral hypoglycaemic drugs. Previously listed for type 1 diabetes. | Nov 2007 | Recommended with restriction | no section in document |
| pioglitazone hydrochloride Type 2 diabetes mellitus in combination with metformin and a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with maximally tolerated… | Nov 2007 | Recommended with restriction | no section in document |
| rosiglitazone maleate Type 2 diabetes mellitus: monotherapy in patients uncontrolled on metformin or unable to take metformin; dual therapy with metformin in patients uncontrolled… | Nov 2007 | Not recommended | no section in document |
| rosiglitazone maleate with metformin hydrochloride Type 2 diabetes mellitus in patients with inadequate glycaemic control despite maximally tolerated doses of metformin alone, or metformin in combination with a… | Jul 2006 | Recommended with restriction | no section in document |
| rosiglitazone maleate with metformin hydrochloride Type 2 diabetes mellitus in patients with inadequate glycaemic control on metformin alone or metformin with sulfonylurea, for dual or triple therapy. | Jul 2006 | Recommended with restriction | no section in document |
| insulin detemir Treatment of Type 1 diabetes requiring intensive insulin therapy with 3 or more injections of insulin per day, including one short-acting insulin. Also for… | Mar 2006 | Recommended with restriction | no section in document |
| insulin glargine Treatment of Type 1 diabetes mellitus in adults and children, and Type 2 diabetes mellitus in adults who require insulin for control of hyperglycaemia. | Mar 2006 | Recommended | no section in document |
| insulin detemir Treatment of diabetes mellitus where used as basal insulin in combination with meal-related short- or rapid-acting insulin. | Jul 2005 | Recommended | no section in document |
Who spoke
Diabetes Australia · National Aboriginal Community Controlled Health Organisation · Australian Diabetes Society · Diabetes Alliance · Australian Institute
What the PBS pays
$4,658M in government benefit over 2024–25, across 122,421,202 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| empagliflozin, empagliflozin with metformin, linagliptin, linagliptin with metformin | $385.4M |
| empagliflozin/metformin | $339.8M |
| dapagliflozin with metformin | $298.9M |
| linagliptin with metformin hydrochloride | $277.7M |
| semaglutide | $260.5M |
| empagliflozin with linagliptin | $250.7M |
| metformin and sitagliptin | $228.6M |
| metformin and saxagliptin | $211.7M |
| saxagliptin with metformin | $211.7M |
| vildagliptin/metformin | $211.3M |
| alogliptin with metformin | $210.8M |
| rosiglitazone maleate with metformin hydrochloride | $210M |
Appraised elsewhere
NICE, in England and Wales, has appraised 11 technologies for this condition, recommending 9 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| canagliflozinCanagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1137 | terminated | 2026-02 |
| empagliflozinEmpagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | terminated | 2024-09 |
| tirzepatideTirzepatide for treating type 2 diabetes | TA924 | recommended restricted | 2023-10 |
| ertugliflozinErtugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | recommended restricted | 2019-06 |
| ertugliflozinErtugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | recommended restricted | 2019-03 |
| dapagliflozinDapagliflozin in triple therapy for treating type 2 diabetes | TA418 | recommended restricted | 2016-11 |
| canagliflozin dapagliflozin and empagliflozinCanagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | recommended restricted | 2016-05 |
| empagliflozinEmpagliflozin in combination therapy for treating type 2 diabetes | TA336 | recommended restricted | 2015-03 |
| canagliflozinCanagliflozin in combination therapy for treating type 2 diabetes | TA315 | recommended restricted | 2014-06 |
| dapagliflozinDapagliflozin in combination therapy for treating type 2 diabetes | TA288 | recommended restricted | 2013-06 |
| continuous subcutaneous insulin infusionContinuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | recommended | 2008-07 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| gliclazideAKM GLICLAZIDE gliclazide 30 mg modified release tablet blister pack | 1991 | 50 |
| glimepirideARX-GLIMEPIRIDE glimepiride 1mg tablet blister pack | 2005 | 43 |
| acarboseACARBOSE GPPL acarbose 100 mg tablet blister pack | 2015 | 10 |
| insulin icodecAWIQLI insulin icodec 1050 U in 1.5 mL solution for injection pre-fill | 2024 | 6 |
| glipizideGLIPIDIAB gipizide 5mg tablets blister pack | 1991 | 2 |
| glibenclamideDAONIL 5mg Tablets | 2000 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 21 of 59 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.